Lisa A. Jackson, MD, MPH

“Kaiser Permanente Washington gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine

Lisa.A.Jackson@kp.org

Curriculum vitae (CV)

Biography

Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.

Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.

Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.

Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.

After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.

Research interests and experience

Vaccines & Infectious Diseases

Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia

Recent publications

Stewart RJ, Flannery B, Chung JR, Gaglani M, Reis M, Zimmerman RK, Nowalk MP, Jackson L, Jackson ML, Monto AS, Martin ET, Belongia EA, McLean HQ, Fry AM, Havers FP Influenza Antiviral Prescribing for Outpatients with an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications during Five Influenza Seasons-United States, 2011-2016 2018 Mar 19;66(7):1035-1041. doi: 10.1093/cid/cix922. PubMed

Sukumaran L, McCarthy NL, Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Jackson L, Klein NP, Naleway AL, McClure DL, Hechter RC, Kawai AT, Glanz JM, Weintraub ES Infant Hospitalizations and Mortality After Maternal Vaccination 2018 Mar;141(3). doi: 10.1542/peds.2017-3310. Epub 2018-02-20. PubMed

Russell K, Chung JR, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Flannery B Influenza vaccine effectiveness in older adults compared with younger adults over five seasons 2018 Feb 28;36(10):1272-1278. doi: 10.1016/j.vaccine.2018.01.045. PubMed

Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Martin ET, Foust A, Sessions W, Berman L, Barnes JR, Spencer S, Fry AM Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018 2018 Feb 16;67(6):180-185. doi: 10.15585/mmwr.mm6706a2. Epub 2018-02-16. PubMed

Widdice LE, Unger ER, Panicker G, Hoagland R, Callahan ST, Jackson LA, Berry AA, Kotloff K, Frey SE, Harrison CJ, Pahud BA, Edwards KM, Mulligan MJ, Sudman J, Bernstein DI Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals 2018 Feb;36(6):881-889. doi: 10.1016/j.vaccine.2017.12.042. Epub 2018-01-03. PubMed

Jackson LA, El Sahly HM, George S, Winokur P, Edwards K, Brady RC, Rouphael N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine 2017 Dec 23 doi: 10.1016/j.vaccine.2017.12.061. PubMed

Storms AD, Chen J, Jackson LA, Nordin JD, Naleway AL, Glanz JM, Jacobsen SJ, Weintraub ES, Klein NP, Gargiullo PM, Fry AM Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults 2017 Dec 16;17(1):208. doi: 10.1186/s12890-017-0552-x. Epub 2017-12-16. PubMed

Jackson ML, Phillips CH, Benoit J, Kiniry E, Madziwa L, Nelson JC, Jackson LA The impact of selection bias on vaccine effectiveness estimates from test-negative studies 2017 Dec 15 doi: 10.1016/j.vaccine.2017.12.022. PubMed

Jackson ML, Phillips CH, Benoit J, Jackson LA, Gaglani M, Murthy K, McLean HQ, Belongia EA, Malosh R, Zimmerman R, Flannery B Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons 2017 Dec 14 doi: 10.1016/j.vaccine.2017.12.014. PubMed

Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, Cheetham TC, Glanz JM, Jackson LA, Klein NP, Naleway AL, Weintraub E, Belongia EA Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12 2017 Sep 25;35(40):5314-5322. doi: 10.1016/j.vaccine.2017.06.069. PubMed